Joseph R. Scalea

Joseph R. Scalea


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
UBUgo Boggi
Ugo Boggi
FVFabio Vistoli
Fabio Vistoli
AAAxel Andres
Axel Andres
HAHelmut P. Arbogast
Helmut P. Arbogast
LBLionel Badet
Lionel Badet
TBThierry Berney
Thierry Berney
The First World Consensus Conference on Pancreas Transplantation provided 49 jury deliberations regarding the impact of pancreas transplantation on the treatment of diabetic patients, and 110 experts’ recommendations for the practice of pancreas transplantation. The main message from this consensus conference is that both simultaneous pancreas-kidney transplantation (SPK) and pancreas transplantation alone can improve long-term patient survival, and all types of pancreas transplantation dramatically improve the quality of life of recipients. Pancreas transplantation may also improve the course of chronic complications of diabetes, depending on their severity. Therefore, the advantages of pancreas transplantation appear to clearly surpass potential disadvantages. Pancreas after kidney transplantation increases the risk of mortality only in the early period after transplantation, but is associated with improved life expectancy thereafter. Additionally, preemptive SPK, when compared to SPK performed in patients undergoing dialysis, appears to be associated with improved outcomes. Time on dialysis has negative prognostic implications in SPK recipients. Increased long-term survival, improvement in the course of diabetic complications, and amelioration of quality of life justify preferential allocation of kidney grafts to SPK recipients. Audience discussions and live voting are available online at the following URL address: http://mediaeventi.unipi.it/category/1st-world-consensus-conference-of-pancreas-transplantation/246.

6 November 2018 in IEEE Journal of Translational Engineering in Health and Medicine
Verified
Journal Article
Open access
JSJoseph R. Scalea
Joseph R. Scalea
SRStephen Restaino
Stephen Restaino
MSMatthew Scassero
Matthew Scassero
GBGil Blankenship
Gil Blankenship
SBStephen T. Bartlett
Stephen T. Bartlett
Norman M. WereleyNorman M. Wereley
Norman M. Wereley
Organ transportation has yet to be substantially innovated. If organs could be moved by drone, instead of ill-timed commercial aircraft or expensive charter flights, lifesaving organs could be transplanted more quickly. A modified, six-rotor UAS was used to model situations relevant to organ transportation. To monitor the organ, we developed novel technologies that provided the real-time organ status using a wireless biosensor combined with an organ global positioning system. Fourteen drone organ missions were performed. Temperatures remained stable and low (2.5 °C). Pressure changes (0.37-0.86 kPa) correlated with increased altitude. Drone travel was associated with less vibration (<;0.5 G) than was observed with fixed-wing flight (>2.0 G). Peak velocity was 67.6 km/h (42 m/h). Biopsies of the kidney taken prior to and after organ shipment revealed no damage resulting from drone travel. The longest flight was 3.0 miles, modeling an organ flight between two inner city hospitals. Organ transportation may be an ideal use-case for drones. With the development of faster, larger drones, long-distance drone organ shipment may result in substantially reduced cold ischemia times, subsequently improved organ quality, and thousands of lives saved.

28 July 2022 in Liver Transplantation
Verified
Journal Article
Open access
ASAlexandra T. Strauss
Alexandra T. Strauss
CSCarolyn N. Sidoti
Carolyn N. Sidoti
TPTanjala S. Purnell
Tanjala S. Purnell
HSHannah C. Sung
Hannah C. Sung
JJJohn W. Jackson
John W. Jackson
AGAyse P. Gurses
Ayse P. Gurses
Racial and ethnic disparities persist in access to the liver transplantation (LT) waiting list; however, there is limited knowledge about underlying system‐level factors that may be responsible for these disparities. Given the complex nature of LT candidate evaluation, a human factors and systems engineering approach may provide insights. We recruited participants from the LT teams (coordinators, advanced practice providers, physicians, social workers, dieticians, pharmacists, leadership) at two major LT centers. From December 2020 to July 2021, we performed ethnographic observations (participant–patient appointments, committee meetings) and semistructured interviews (N = 54 interviews, 49 observation hours). Based on findings from this multicenter, multimethod qualitative study combined with the Systems Engineering Initiative for Patient Safety 2.0 (a human factors and systems engineering model for health care), we created a conceptual framework describing how transplant work system characteristics and other external factors may improve equity in the LT evaluation process. Participant perceptions about listing disparities described external factors (e.g., structural racism, ambiguous national guidelines, national quality metrics) that permeate the LT evaluation process. Mechanisms identified included minimal transplant team diversity, implicit bias, and interpersonal racism. A lack of resources was a common theme, such as social workers, transportation assistance, non–English‐language materials, and time (e.g., more time for education for patients with health literacy concerns). Because of the minimal data collection or center feedback about disparities, participants felt uncomfortable with and unadaptable to unwanted outcomes, which perpetuate disparities. We proposed transplant center–level solutions (i.e., including but not limited to training of staff on health equity) to modifiable barriers in the clinical work system that could help patient navigation, reduce disparities, and improve access to care. Our findings call for an urgent need for transplant centers, national societies, and policy makers to focus efforts on improving equity (tailored, patient‐centered resources) using the science of human factors and systems engineering.

11 September 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JSJoseph R. Scalea
Joseph R. Scalea
SRStephen Restaino
Stephen Restaino
MSMatthew Scassero
Matthew Scassero
SBStephen T. Bartlett
Stephen T. Bartlett
Norman M. WereleyNorman M. Wereley
Norman M. Wereley
Technical, immunologic, and patient care advancements have improved transplant outcomes, but geography and organ transportation remain impediments to access to transplantation. Organs are moved using a complex network of couriers, commercial aircraft, and transplant personnel. Reliance on commercial aircraft schedules and couriers add cold ischemia time (CIT) and may prohibit transplantation altogether.1 Private charters can be used, however this comes at great expense.

11 December 2017 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
JSJoseph R. Scalea
Joseph R. Scalea
LPLauren Pettinato
Lauren Pettinato
BFBlythe Fiscella
Blythe Fiscella
ABAmanda Bartosic
Amanda Bartosic
APAllison Piedmonte
Allison Piedmonte
SBStephen T. Bartlett
Stephen T. Bartlett

15 March 2023 in Transplantation Direct
Verified
Journal Article
Open access
AYAshley Bs Yoo
Ashley Bs Yoo
ARAlexandria Bs Riedel
Alexandria Bs Riedel
IQIan Bs Qian
Ian Bs Qian
ABAmanda Mba Bartosic
Amanda Mba Bartosic
RSRudi Bs Soltani
Rudi Bs Soltani
JSJoseph R. Scalea
Joseph R. Scalea
Background.: Pancreas transplantation offers patients with diabetes an opportunity for glucose homeostasis. Current blood tests to surveil for rejection have poor sensitivity and specificity for identifying rejection, and pancreas biopsies are challenging and associated with morbidity and graft loss. Donor-derived cell-free DNA (dd-cfDNA) is shed from transplanted organs and detectable in peripheral blood. Thus, a potential dd-cfDNA blood test assessing rejection would be clinically advantageous. Methods.: One hundred eighty-one dd-cfDNA samples (n) were collected from 77 patients (N) up to 132 mo posttransplant. Results.: The median dd-cfDNA level among all subjects was 0.28% (0.13%, 0.71%). In simultaneous pancreas-kidney (SPK) transplant recipients, the median dd-cfDNA level was 0.29% (0.13%, 0.71%), and it was 0.23% (0.08%, 0.71%) in pancreas transplant alone (PTA) recipients. When isolating for when without infection or rejection, the median dd-cfDNA level was 0.28% (0.13%, 0.64%) for SPK and 0.20% (0.00%, 0.32%) for PTA. Both transplant types approached 1.0% ≤1 mo posttransplant followed by a decrease in median dd-cfDNA. During episodes of rejection or infection, median dd-cfDNA levels were greater among all transplant types. Conclusions.: The mean dd-cfDNA level for all pancreas transplant recipients is 1.0%), regardless of SPK or PTA. Early posttransplant dd-cfDNA levels are transiently higher than later measurements. Dd-cfDNA elevation also correlates with rejection and infection and thus is a promising biomarker for surveilling pancreas transplant dysfunction.